Amneal (AMRX) director exercises RSUs, now holds 260,252 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Amneal Pharmaceuticals director John Kiely reported compensation-related equity activity. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares at a stated price of $0.00 per share. The Form 4 also shows a grant of 19,824 restricted stock units on May 6, 2026, each representing a right to receive one share of Class A Common Stock. After these transactions, Kiely directly owns 260,252 Class A Common Stock shares, with no remaining restricted stock units reported in this filing.

Insider Trade Summary

34,819 shares exercised/converted

Mixed 3 txns

Insider Kiely John

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	34,819	$0.00	--
Exercise	Class A Common Stock	34,819	$0.00	--
Grant/Award	Restricted Stock Units	19,824	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Class A Common Stock — 260,252 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Key Figures

RSUs Exercised: 34,819 units New RSU Grant: 19,824 units Shares Held After: 260,252 shares +1 more

4 metrics

RSUs Exercised 34,819 units Converted into Class A Common Stock on May 7, 2026

New RSU Grant 19,824 units Restricted Stock Units granted on May 6, 2026

Shares Held After 260,252 shares Class A Common Stock directly owned after transactions

Exercise Price $0.00 per unit Stated transaction price for RSU exercise

Key Terms

Restricted Stock Units, Class A Common Stock, grant, award, or other acquisition, Exercise or conversion of derivative security

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A Common Stock financial

"receive one share of the Issuer's Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Form 4 Insider Transactions: What Each Field Means →

05/08/2026 - 04:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kiely John

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER

NEW JERSEY

08807

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	05/07/2026		M		34,819	A	⁽¹⁾	260,252	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	05/07/2026		M			34,819	⁽²⁾	⁽²⁾	Class A Common Stock	34,819	$0	0	D
Restricted Stock Units	⁽¹⁾	05/06/2026		A		19,824		⁽³⁾	⁽³⁾	Class A Common Stock	19,824	$0	19,824	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

3. Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Amneal (AMRX) director John Kiely report?

John Kiely reported equity compensation activity, not open-market trades. He exercised 34,819 restricted stock units into Class A Common Stock and received a separate grant of 19,824 new restricted stock units, all at a stated price of $0.00 per unit.

How many Amneal (AMRX) shares does John Kiely own after this Form 4?

After the reported transactions, John Kiely directly holds 260,252 shares of Amneal Class A Common Stock. This figure reflects his position following the restricted stock unit exercise and grant disclosed in the Form 4 filing.

Were John Kiely’s Amneal (AMRX) transactions open-market buys or sells?

The transactions were not open-market buys or sells. They were compensation-related events: an exercise of 34,819 restricted stock units into Class A Common Stock and a grant of 19,824 new restricted stock units, both recorded at $0.00 per unit.

What do Amneal (AMRX) restricted stock units represent in this Form 4?

Each restricted stock unit in this Form 4 represents a contingent right to receive one share of Amneal’s Class A Common Stock. Units are granted as equity compensation and convert into shares upon vesting and exercise on the terms described in the award.

Did John Kiely retain derivative positions in Amneal (AMRX) after this filing?

The filing shows no remaining restricted stock units after the exercise of 34,819 units, and the derivative summary is empty. That indicates no additional derivative equity positions are reported for John Kiely in this specific Form 4.